Hepatic ImpairmentPhase 1NCT01222455
A Study of Fostamatinib in Subjects With Impaired Hepatic (Liver) Function
A Phase 1 study testing Fostamatinib in people with Hepatic Impairment and Healthy Volunteers, run by AstraZeneca at 1 site in United States.
Trial summary
A study to evaluate the amount of fostamatinib in the blood in subjects with impaired hepatic (liver) function compared with healthy volunteers with normal liver function. The study will also evaluate safety and tolerability in subjects with hepatic impairment. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Hepatic Impairment, Healthy Volunteers, Pharmacokinetics
- What is being tested?
- Fostamatinib
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 32 participants
- Where
- 1 siteUnited States
- Study dates
- Oct 2010to Jun 2011
- Phase
- Phase 1
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Males and females (non child-bearing potential) aged 18 years or more, with a weight of at least 50 kg and body mass index (BMI) between 18 and 40 kg/m2 inclusive
- Healthy subjects only: good health as determined by a medical history, physical examination , ECG and clinical laboratory evaluations
- Healthy subjects only: negative results for serum hepatitis B and C
Who cannot join
- Subjects who have received any medications known to alter drug absorption or elimination within 30 days of first dose.
- Subjects who smoke more than 10 cigarettes or equivalent per day
- Absolute neutrophil count <2500/mm3
- Abnormal vital signs, additional systemic disease (eg, cardiac, or renal disease) or abnormal laboratory findings that are judged to be clinically significant by the investigator
- Healthy volunteers only: use of prescribed medications within 2 weeks of first dose or use of non-prescribed medications within 1 week of first dose
- Hepatic subjects only: fluctuating or rapidly deteriorating hepatic function
Trial locations and contacts
1 site in 1 country.
About this study
Official title: An Open-label, Single-center Study to Assess the Pharmacokinetics of R406 in Subjects With Hepatic Impairment and in Healthy Subjects Following Administration of a Single Dose of Fostamatinib Disodium 150 mg
A study to evaluate the amount of fostamatinib in the blood in subjects with impaired hepatic (liver) function compared with healthy volunteers with normal liver function. The study will also evaluate safety and tolerability in subjects with hepatic impairment.
- Being tested
- Fostamatinib
- Keywords
- Phase 1, Healthy volunteers, Volunteers with hepatic impairment, Pharmacokinetics, Fostamatinib
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
FostamatinibDrug
Oral tablets, single dose
| Study group | Role | What they receive |
|---|---|---|
| 1 | Experimental | Mild hepatic impairment Receives: Drug: Fostamatinib |
| 2 | Experimental | Moderate hepatic impairment Receives: Drug: Fostamatinib |
| 3 | Experimental | Severe hepatic impairment Receives: Drug: Fostamatinib |
| 4 | Experimental | Matched healthy volunteers with normal hepatic function Receives: Drug: Fostamatinib |
What is being measured
The primary outcome is the main question the study is designed to answer.
To determine plasma PK parameters of R406 in subjects with varying degrees of hepatic impairment as well as in healthy subjects (including but not limited to: AUC, tmax, Cmax and terminal elimination half life (t1/2))
Measured: From pre-dose until 120 hours after the single dose
Secondary outcomes (1)
To investigate safety and tolerability of fostamatinib 150mg: adverse event monitoring, vital signs, physical examinations, clinical laboratory tests, ECGs.
Measured: From pre-dose until 120 hours after the single dose
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Oct 2010 (estimated)
- Study startOct 2010
- Primary completionJun 2011
- Study completionJun 2011
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Hepatic ImpairmentStudies of the same condition, open and under way.
- More trials run by AstraZenecaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Basic science
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 32 participants (estimated)
Sponsor and investigators
- Lead sponsor
- AstraZeneca
- Sponsor type
- Industry (pharma, biotech, devices)
- Investigators
- Thomas Marbury, MD, Principal investigator, Orlando Clinical Research Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01222455
- Sponsor's protocol ID
- D4300C00010
- Status last verified
- Jul 2011
- First submitted
- 15 Oct 2010
- Last updated
- 6 Jul 2011
- Results posted
- No
Publications
Martin P, Oliver S, Gillen M, Marbury T, Millson D. Pharmacokinetic Properties of Fostamatinib in Patients With Renal or Hepatic Impairment: Results From 2 Phase I Clinical Studies. Clin Ther. 2015 Dec 1;37(12):2823-36. doi: 10.1016/j.clinthera.2015.09.016. Epub 2015 Oct 27.
PubMed 26519231